SEARCH

SEARCH BY CITATION

References

  • 1
    Cordoba J, Flavia M, Jacas C et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J Hepatol 2003; 39: 231238.
  • 2
    Forton DM, Allsop JM, Main J et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358: 3839.
  • 3
    Forton DM, Thomas HC, Murphy CA et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433439.
  • 4
    Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9: 847854.
  • 5
    Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35: 440446.
  • 6
    Kramer L, Bauer E, Funk G et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002; 37: 349354.
  • 7
    McAndrews MP, Farcnik K, Carlen P et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801808.
  • 8
    Weissenborn K, Krause J, Bokemeyer M et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845851.
  • 9
    Taylor MJ, Letendre SL, Schweinsburg BC et al. Hepatitis C virus infection is associated with reduced white matter N-acetylaspartate in abstinent methamphetamine users. J Int Neuropsychol Soc 2004; 10: 110113.
  • 10
    Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000; 157: 683694.
  • 11
    Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 2004; 78: 51705183.
  • 12
    Thomas HC, Torok ME, Forton DM, Taylor-Robinson SD. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999; 31 (Suppl. 1): 152159.
  • 13
    Barkhuizen A, Rosen HR, Wolf S et al. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol 1999; 94: 13551360.
  • 14
    Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264270.
  • 15
    Dwight MM, Kowdley KV, Russo JE et al. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000; 49: 311317.
  • 16
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209212.
  • 17
    Goh J, Coughlan B, Quinn J, O'Keane JC, Crowe J. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1999; 11: 833838.
  • 18
    Goulding C, O'Connell P, Murray FE. Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition. Eur J Gastroenterol Hepatol 2001; 13: 507511.
  • 19
    Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998; 93: 785789.
    Direct Link:
  • 20
    Kraus MR, Schafer A, Csef H, Scheurlen M, Faller H. Emotional state, coping styles, and somatic variables in patients with chronic hepatitis C. Psychosomatics 2000; 41: 377384.
  • 21
    Obhrai J, Hall Y, Anand BS. Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol 2001; 32: 413417.
  • 22
    Spiegel BM, Younossi ZM, Hays RD et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790800.
  • 23
    Ware JE Jr, Bayliss MS, Mannocchia M, Davis GL. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 550555.
  • 24
    Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000; 30 (Suppl. 1): S77S84.
  • 25
    Heaton RK, Grant I, Butters N et al. The HNRC 500 – neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1995; 1: 231251.
  • 26
    Letendre SL, Cherner M, Ellis RJ et al. The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 2005; 19 (Suppl. 3): S72S78.
  • 27
    Cherner M, Letendre S, Heaton RK et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005; 64: 13431347.
  • 28
    Ryan EL, Morgello S, Isaacs K, Naseer M, Gerits P. Neuropsychiatric impact of hepatitis C on advanced HIV. Neurology 2004; 62: 957962.
  • 29
    Von Giesen HJ, Heintges T, Abbasi-Boroudjeni N et al. Psychomotor slowing in hepatitis C and HIV infection. J Acquir Immune Defic Syndr 2004; 35: 131137.
  • 30
    McHutchison JG, Ware JE Jr, Bayliss MS et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140147.
  • 31
    Hays RD, Cunningham WE, Sherbourne CD et al. Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study. Am J Med 2000; 108: 714722.
  • 32
    Miners AH, Sabin CA, Mocroft A et al. Health-related quality of life in individuals infected with HIV in the era of HAART. HIV Clin Trials 2001; 2: 484492.
  • 33
    Sherbourne CD, Hays RD, Fleishman JA et al. Impact of psychiatric conditions on health-related quality of life in persons with HIV infection. Am J Psychiatry 2000; 157: 248254.
  • 34
    Tozzi V, Balestra P, Galgani S et al. Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Human Retroviruses 2003; 19: 643652.
  • 35
    Nelson HE, Willison J. National Adult Reading Test (NART) Test Manual, 2nd edn. Berkshire, UK: The NFER-NELSON Publishing Co., 1991.
  • 36
    Reitan RM. The validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958; 9: 127130.
  • 37
    Cysique LA, Maruff P, Darby D, Brew BJ. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol 2006; 21: 185194.
  • 38
    Falleti MG, Maruff P, Collie A, Darby DG, McStephen M. Qualitative similarities in cognitive impairment associated with 24 h of sustained wakefulness and a blood alcohol concentration of 0.05%. J Sleep Res 2003; 12: 265274.
  • 39
    Darby D, Maruff P, Collie A, McStephen M. Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology 2002; 59: 10421046.
  • 40
    Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003; 9: 419428.
  • 41
    Fayers PM, Curran D, Machin D. Incomplete quality of life data in randomized trials: missing items. Stat Med 1998; 17: 679696.
  • 42
    Tabachnick BG, Fidell LS. Using Multivariate Statistics, 4th edn. MA/USA, Needham Heights: Allyn and Bacon, 2001.
  • 43
    Lovibond SH, Lovibond PF. Manual for the Depression Anxiety Stress Scales, 2nd edn. Sydney, Australia: Psychology Foundation Monograph, 1995.
  • 44
    Bayliss MS, Gandek B, Bungay KM et al. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998; 7: 3955.
  • 45
    Ware JE, Kosinski M. SF-36 (R) Physical and Mental Health Summary Scales: a Manual for Users of Version 1, 2nd edn. Lincoln, RI: QualityMetric Incorporated, 2001.
  • 46
    Brazier J, Roberts J, Tsuchiya A, Busschbach J A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004; 13: 873884.
  • 47
    Miller MD, Ferris DG. Measurement of subjective phenomena in primary care research: the Visual Analogue Scale. Fam Pract Res J 1993; 13: 1524.
  • 48
    Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. New York, NY: Academic Press, 1988.
  • 49
    Howell DC. Statistical Methods for Psychology, 5th edn. CA/USA, Pacific Grove: Duxbury, 2002.
  • 50
    Ingraham LJ, Aiken CB. An empirical approach to determining criteria for abnormality in test batteries with multiple measures. Neuropsychology 1996; 10: 120124.
  • 51
    Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrica 1951; 16: 297334.
  • 52
    Nunnally JC. Psychometric Theory. New York, NY: McGraw-Hill, 1978.
  • 53
    Altman DG. Practical Statistics for Medical Research, 1st edn. London, UK: Chapman & Hall, 1991.
  • 54
    ABS National Health Survey SF-36 Population Norms. Canberra, Australia: Australian Bureau of Statistics (ABS), 1997.
  • 55
    Brew BJ.. HIV Neurology. New York, NY: Oxford University Press, 2001.
  • 56
    Eyster ME, Diamondstone LS, Lien JM et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 602610.
  • 57
    Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. The Multicenter Hemophilia Cohort Study. Blood 1994; 84: 10201023.
  • 58
    Rogers RD, Robbins TW. Investigating the neurocognitive deficits associated with chronic drug misuse. Curr Opin Neurobiol 2001; 11: 250257.
  • 59
    Fleming CA, Christiansen D, Nunes D et al. Health-related quality of life of patients with HIV disease: impact of hepatitis C coinfection. Clin Infect Dis 2004; 38: 572578.
  • 60
    Fontana RJ, Bieliauskas LA, Back-Madruga C et al. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol 2005; 43: 614622.
  • 61
    Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005; 100: 643651.
    Direct Link:
  • 62
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372374.
  • 63
    Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002; 21: 271292.
  • 64
    Brazier J, Usherwood T, Harper R, Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 1998; 51: 11151128.